Fig. 3.
Kaplan-Meier plots showing the time to progression dependent on early Bcr-Abl levels.
Ph+ ALL patients treated with imatinib (only good responders) were allocated to either of 2 groups dependent upon their Bcr-Abl/GAPDH ratio in BM above or below 10−2 after 4 weeks of therapy. The difference was significant (P = .0002).
